Department of Anesthesiology, Qilu Hospital of Shandong University, Jinan, China.
The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan, China.
J Cell Mol Med. 2021 Jun;25(11):5202-5219. doi: 10.1111/jcmm.16523. Epub 2021 May 4.
Pulmonary arterial hypertension (PAH) featured a debilitating progressive disorder. Here, we intend to determine diagnosis-valuable biomarkers for PAH and decode the fundamental mechanisms of the biological function of these markers. Two mRNA microarray profiles (GSE70456 and GSE117261) and two microRNA microarray profiles (GSE55427 and GSE67597) were mined from the Gene Expression Omnibus platform. Then, we identified the differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs), respectively. Besides, we investigated online miRNA prediction tools to screen the target gene of DEMs. In this study, 185 DEGs and three common DEMs were screened as well as 1266 target genes of the three DEMs were identified. Next, 16 overlapping dysregulated genes from 185 DEGs and 1266 target gene were obtained. Meanwhile, we constructed the miRNA gene regulatory network and determined miRNA-508-3p-NR4A3 pair for deeper exploring. Experiment methods verified the functional expression of miR-508-3p in PAH and its signalling cascade. We observed that ectopic miR-508-3p expression promotes proliferation and migration of pulmonary artery smooth muscle cell (PASMC). Bioinformatic, dual-luciferase assay showed NR4A3 represents directly targeted gene of miR-508-3p. Mechanistically, we demonstrated that down-regulation of miR-508-3p advances PASMC proliferation and migration via inducing NR4A3 to activate MAPK/ERK kinase signalling pathway. Altogether, our research provides a promising diagnosis of predictor and therapeutic avenues for patients in PAH.
肺动脉高压(PAH)是一种进行性衰弱性疾病。在这里,我们旨在确定 PAH 的有价值的诊断生物标志物,并阐明这些标志物的生物学功能的基本机制。从基因表达综合数据库平台挖掘了两个 mRNA 微阵列图谱(GSE70456 和 GSE117261)和两个 microRNA 微阵列图谱(GSE55427 和 GSE67597)。然后,我们分别鉴定了差异表达基因(DEGs)和差异表达 microRNAs(DEMs)。此外,我们研究了在线 microRNA 预测工具,以筛选 DEMs 的靶基因。在这项研究中,筛选了 185 个 DEGs 和三个常见的 DEMs,以及三个 DEMs 的 1266 个靶基因。接下来,从 185 个 DEG 和 1266 个靶基因中获得了 16 个重叠失调基因。同时,我们构建了 microRNA 基因调控网络,并确定了 microRNA-508-3p-NR4A3 对,以进行更深入的研究。实验方法验证了 miR-508-3p 在 PAH 中的功能表达及其信号级联。我们观察到,异位 miR-508-3p 表达促进肺动脉平滑肌细胞(PASMC)的增殖和迁移。生物信息学、双荧光素酶报告基因检测显示,NR4A3 是 miR-508-3p 的直接靶基因。从机制上讲,我们证明,通过诱导 NR4A3 激活 MAPK/ERK 激酶信号通路,下调 miR-508-3p 可促进 PASMC 的增殖和迁移。总之,我们的研究为 PAH 患者提供了有前途的诊断预测因子和治疗途径。